- Home
- NML vs VALN Comparison
NML vs VALN Comparison
Compare NML & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- VALN
- Stock Information
- Founded
- NML 2012
- VALN 2012
- Country
- NML United States
- VALN France
- Employees
- NML N/A
- VALN N/A
- Industry
- NML Finance/Investors Services
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NML Finance
- VALN Health Care
- Exchange
- NML Nasdaq
- VALN Nasdaq
- Market Cap
- NML 461.2M
- VALN 378.3M
- IPO Year
- NML N/A
- VALN 2021
- Fundamental
- Price
- NML $9.28
- VALN $4.42
- Analyst Decision
- NML
- VALN Strong Buy
- Analyst Count
- NML 0
- VALN 2
- Target Price
- NML N/A
- VALN $18.50
- AVG Volume (30 Days)
- NML 219.3K
- VALN 25.3K
- Earning Date
- NML 01-01-0001
- VALN 11-07-2024
- Dividend Yield
- NML 9.75%
- VALN N/A
- EPS Growth
- NML N/A
- VALN N/A
- EPS
- NML N/A
- VALN N/A
- Revenue
- NML N/A
- VALN $176,817,979.00
- Revenue This Year
- NML N/A
- VALN $24.30
- Revenue Next Year
- NML N/A
- VALN $16.05
- P/E Ratio
- NML N/A
- VALN N/A
- Revenue Growth
- NML N/A
- VALN N/A
- 52 Week Low
- NML $6.09
- VALN $4.27
- 52 Week High
- NML $7.33
- VALN $11.96
- Technical
- Relative Strength Index (RSI)
- NML 77.71
- VALN 25.94
- Support Level
- NML $8.87
- VALN $4.45
- Resistance Level
- NML $9.14
- VALN $4.73
- Average True Range (ATR)
- NML 0.15
- VALN 0.20
- MACD
- NML 0.05
- VALN -0.07
- Stochastic Oscillator
- NML 94.87
- VALN 9.03
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.